10-K: Vivos Therapeutics Reports Full Year 2023 Results, Navigates Market Challenges and Strategic Shifts

Vivos Therapeutics reports a net loss of $13.6 million for 2023, while implementing strategic changes and navigating market headwinds.

Summary

• Vivos Therapeutics reported a net loss of $13.6 million for the year ended December 31, 2023, compared to a net loss of $23.8 million in 2022.
• The company's revenue decreased by 14% to $13.8 million in 2023, down from $16 million in 2022, primarily due to a decline in product revenue.
• Operating expenses decreased by approximately $9.5 million, driven by reductions in general and administrative and sales and marketing costs.
• The company experienced a decrease in appliance sales and VIP enrollments, but saw an increase in revenue from sleep testing services and sponsorship/training programs.
• Vivos has identified a material weakness in its internal control over financial reporting and is implementing a remediation plan.
• The company is focused on expanding its market reach through DME distribution agreements and strategic collaborations.
• Vivos is also working to increase public awareness of OSA and its treatment options, and to cultivate referral sources among physicians and dentists.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as improved net loss and strategic collaborations, the decrease in revenue and the identification of a material weakness in internal controls temper the overall sentiment. The company is facing challenges but is also taking steps to address them.

Positives

• The company's net loss improved significantly year-over-year.
• Operating expenses were reduced by $9.5 million.
• The company secured a nationwide distribution agreement with Lincare.
• Vivos CARE appliances received FDA clearance for treating moderate and severe OSA.
• The company is expanding its product portfolio and strategic collaborations.

Negatives

• Revenue decreased by 14% year-over-year.
• The company experienced a decrease in appliance sales and VIP enrollments.
• The company has identified a material weakness in its internal control over financial reporting.
• The company is subject to potential delisting from Nasdaq.

Risks

• The company has a limited operating history and continues to refine its business model.
• The company has a history of operating losses and may not achieve profitability.
• The company will need to raise additional capital to fund and grow its business.
• The company faces risks from negative publicity from unregistered oral appliances.
• The company may not be able to successfully implement its growth strategies.
• The company faces significant competition in the market for treating sleep breathing disorders.
• The company's products and third-party contract manufacturing activities are subject to extensive governmental regulation.
• The market price of the company's common stock has been and may continue to be highly volatile.

Future Outlook

The company aims to be a global leader in providing non-surgical, non-invasive, and low-cost alternatives for patients with dentofacial abnormalities and/or mild to severe OSA and snoring in adults. The company plans to expand public awareness, cultivate referral sources, drive new patients to VIP practices, achieve full insurance payment for Vivos Method treatment, and expand market penetration with DME distribution agreements.

Management Comments

• The company is focused on expanding its market reach through DME distribution agreements and strategic collaborations.
• The company is also working to increase public awareness of OSA and its treatment options, and to cultivate referral sources among physicians and dentists.

Industry Context

The global sleep apnea devices market is valued at $3.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. Vivos is positioning itself to capture a share of this market by offering a non-surgical, non-invasive treatment option for OSA.

Comparison to Industry Standards

• Vivos competes with established companies in the sleep apnea market, including ResMed and Philips, which offer CPAP devices and other treatments.
• Unlike traditional treatments, Vivos offers a non-surgical, non-invasive approach with the potential for lasting results.
• The company's focus on a multidisciplinary approach and collaboration with dentists and other healthcare professionals sets it apart from some competitors.
• Vivos's technology has been the subject of over 60 peer-reviewed articles in the medical, dental and orthodontic literature.

Legal Proceedings

• The company is involved in ongoing litigation with Ortho-Tain, Inc. regarding false and defamatory statements.
• The company is also involved in litigation with Ortho-Tain, Inc. in the United States District Court for the Northern District of Illinois.
• The company is involved in arbitration with its former Chief Medical Officer, Dr. G. Dave Singh.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to market conditions and company performance.
• Employees may be affected by cost-cutting measures and strategic shifts.
• Customers (VIP dentists) may benefit from new products and services, but may also be impacted by changes in pricing and support.
• Suppliers may be affected by changes in the company's sourcing strategy.

Next Steps

• The company will continue to implement its remediation plan to address the material weakness in internal control over financial reporting.
• The company will focus on expanding its market reach through DME distribution agreements and strategic collaborations.
• The company will continue to drive medical and dental community awareness of The Vivos Method.
• The company will invest in research and development to drive innovation and expand indications.

Key Dates

Keywords

Vivos Therapeutics, Obstructive Sleep Apnea, OSA, Sleep Apnea, Oral Appliances, Vivos Method, VIP Program, DME, FDA Clearance, Financial Results